BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

760 related articles for article (PubMed ID: 19472396)

  • 1. The 2008 World Health Organization classification system for myeloproliferative neoplasms: order out of chaos.
    Tefferi A; Thiele J; Vardiman JW
    Cancer; 2009 Sep; 115(17):3842-7. PubMed ID: 19472396
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Classification and diagnosis of myeloproliferative neoplasms: the 2008 World Health Organization criteria and point-of-care diagnostic algorithms.
    Tefferi A; Vardiman JW
    Leukemia; 2008 Jan; 22(1):14-22. PubMed ID: 17882280
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Essential thrombocythemia, polycythemia vera, and myelofibrosis: current management and the prospect of targeted therapy.
    Tefferi A
    Am J Hematol; 2008 Jun; 83(6):491-7. PubMed ID: 18429051
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Diagnostic algorithm in chronic myeloproliferative diseases (CMPD)].
    Haferlach T; Bacher U; Kern W; Schnittger S; Haferlach C
    Med Klin (Munich); 2007 Sep; 102(9):770-7. PubMed ID: 17879017
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloproliferative neoplasms: contemporary diagnosis using histology and genetics.
    Tefferi A; Skoda R; Vardiman JW
    Nat Rev Clin Oncol; 2009 Nov; 6(11):627-37. PubMed ID: 19806146
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Classification and diagnosis of myeloproliferative neoplasms according to the 2008 World Health Organization criteria.
    Wadleigh M; Tefferi A
    Int J Hematol; 2010 Mar; 91(2):174-9. PubMed ID: 20191332
    [TBL] [Abstract][Full Text] [Related]  

  • 7. WHO bone marrow features and European clinical, molecular, and pathological (ECMP) criteria for the diagnosis of myeloproliferative disorders.
    Michiels JJ; De Raeve H; Hebeda K; Lam KH; Berneman Z; Schroyens W; Schwarz J
    Leuk Res; 2007 Aug; 31(8):1031-8. PubMed ID: 17367853
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modern diagnostics in chronic myeloproliferative diseases (CMPDs).
    Haferlach T; Kern W; Schnittger S; Schoch C
    Ann Hematol; 2004; 83 Suppl 1():S59-61. PubMed ID: 15124674
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Classification of myeloid leukemias].
    Kuriyama K
    Nihon Rinsho; 2009 Oct; 67(10):1853-62. PubMed ID: 19860179
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pathogenetic mechanisms in chronic myeloproliferative disorders: polycythemia vera, essential thrombocythemia, agnogenic myeloid metaplasia, and chronic myelogenous leukemia.
    Tefferi A
    Semin Hematol; 1999 Jan; 36(1 Suppl 2):3-8. PubMed ID: 9930550
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Molecular diagnosis of chronic myeloproliferative diseases and myelodysplastic syndromes].
    Bock O
    Verh Dtsch Ges Pathol; 2007; 91():140-53. PubMed ID: 18314608
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Molecular pathology of myeloproliferative neoplasms.
    Klco JM; Vij R; Kreisel FH; Hassan A; Frater JL
    Am J Clin Pathol; 2010 Apr; 133(4):602-15. PubMed ID: 20231614
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Atypical myeloproliferative disorders: diagnosis and management.
    Tefferi A; Elliott MA; Pardanani A
    Mayo Clin Proc; 2006 Apr; 81(4):553-63. PubMed ID: 16610578
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Oncogenic signals as treatment targets in classic myeloproliferative neoplasms.
    Tefferi A; Levine RL; Kantarjian H
    Biol Blood Marrow Transplant; 2009 Jan; 15(1 Suppl):114-9. PubMed ID: 19147089
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Advances in understanding and management of myeloproliferative neoplasms.
    Vannucchi AM; Guglielmelli P; Tefferi A
    CA Cancer J Clin; 2009; 59(3):171-91. PubMed ID: 19369682
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Chronic myeloproliferative disorders. The new WHO classification].
    Thiele J; Kvasnicka HM
    Pathologe; 2001 Nov; 22(6):429-43. PubMed ID: 11766643
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Oncogenes in myeloproliferative disorders.
    Tefferi A; Gilliland DG
    Cell Cycle; 2007 Mar; 6(5):550-66. PubMed ID: 17351342
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The World Health Organization (WHO) classification of tumors of the hematopoietic and lymphoid tissues: an overview with emphasis on the myeloid neoplasms.
    Vardiman JW
    Chem Biol Interact; 2010 Mar; 184(1-2):16-20. PubMed ID: 19857474
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Classification of chronic myeloid disorders: from Dameshek towards a semi-molecular system.
    Tefferi A; Gilliland G
    Best Pract Res Clin Haematol; 2006; 19(3):365-85. PubMed ID: 16781478
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The impact of clinicopathological studies on staging and survival in essential thrombocythemia, chronic idiopathic myelofibrosis, and polycythemia rubra vera.
    Kvasnicka HM; Thiele J
    Semin Thromb Hemost; 2006 Jun; 32(4 Pt 2):362-71. PubMed ID: 16810612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 38.